Journal Mobile Options
Table of Contents
Vol. 192, No. 4, 1996
Issue release date: 1996
Section title: Pharmacology and Treatment
Dermatology 1996;192:337–342
(DOI:10.1159/000246407)

Insulin-Like Growth Factor Axis, Bone and Collagen Turnover in Children with Atopic Dermatitis Treated with Topical Glucocorticosteroids

Wolthers O.D. · Heuck C. · Ternowitz T. · Heickendorff L. · Nielsen H.K. · Frystyk J.
aDepartment of Paediatrics and bInstitut of Experimental Clinical Research, Aarhus University Hospital, cDepartment of Dermatology, Marselisborg Hospital, dUniversity Department of Clinical Biochemistry and eAarhus Bone and Mineral Research Group, University Department of Endocrinology and Metabolism, Aarhus Amtssygehus, Aarhus, Denmark

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Pharmacology and Treatment

Received: 8/18/1995
Accepted: 11/10/1995
Published online: 10/7/2009

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: http://www.karger.com/DRM

Abstract

Background: Topical glucocorticosteroids are widely used in the treatment of children with atopic dermatitis. Due to percutaneous absorption, these agents may become systemically available and cause inhibition of growth in children. However, the mechanisms responsible for the growth-suppressive effect are not fully understood. Objective: To evaluate whether treatment with topical budesonide has any adverse effects on growth-hormone-dependent serum levels of insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein 3 (IGFBP-3), and on the serum markers of bone and collagen turnover osteocalcin, the carboxy-terminal propeptide of type I collagen (PICP), the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen (ICTP) and the amino-terminal propeptide of type III procollagen (PIIINP). Methods: 13 children (mean age 9.5 years) with atopic dermatitis were studied in an open longitudinal trial with run-in and budesonide treatment periods of 2 weeks’ duration. During the run-in, only emollient was used. During the treatment period, budesonide cream 0.025% followed by emollient were applied twice daily all over the body except on the face. At day 14 of each period, blood samples were taken and eczema was scored according to a severity index based on extent and activity of the disease. Results: Compared to the run-in, budesonide treatment was associated with a statistically significant reduction in mean severity index (p = 0.002). No statistically significant effects on serum levels of IGF-I, IGFBP-3, osteocalcin or ICTP were observed. The serum concentrations of PICP and PIIINP were reduced with (mean ± 1 SD) 43 ± 64 μg/l (95% confidence interval 3.5-80 μg/l, p = 0.03, t = 2.4, d.f. = 12) and 1.2 ± 1.5 μg/l (95% confidence interval 0.3–2.1 μg/I, p = 0.01, t = 3.0, d.f. = 12), respectively. Conclusion: Type I and III collagen turnover may be suppressed during short-term treatment with topical budesonide in children with atopic eczema. Clinical implications need further study.


  

Author Contacts

Ole D. Wolthers, MD, Siriusvej 9, DK-8270 Højbjerg (Denmark)

  

Article Information

Received: August 18, 1995
Accepted: November 10, 1995
Published online: October 07, 2009
Number of Print Pages : 6

  

Publication Details

Dermatology

Vol. 192, No. 4, Year 1996 (Cover Date: 1996)

Journal Editor: Saurat J.-H. (Geneva)
ISSN: 1018-8665 (Print), eISSN: 1421-9832 (Online)

For additional information: http://www.karger.com/DRM


Article / Publication Details

First-Page Preview
Abstract of Pharmacology and Treatment

Received: 8/18/1995
Accepted: 11/10/1995
Published online: 10/7/2009

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: http://www.karger.com/DRM


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.